Literature DB >> 2663348

Predisposing factors in corneal graft rejection.

F Hoffmann1, T Pahlitzsch.   

Abstract

During a period of 12 years, 390 patients were treated with perforating keratoplasty and given regular annual follow-ups. Of these, 357 records were evaluated, and there was a 20% incidence of immunoreactions. The transplants were assessed according to four criteria and subdivided into a low-risk and a high-risk group. For high-risk patients, the relative risk of developing an immunoreaction was 2.9 times greater with subdivision according to the preoperative diagnosis, 2.1 times greater with a transplant diameter of 7.5 mm or more, 2.6 times greater with compatibility between fewer than two HLA-B or -DR antigens of the donor and recipient, and 4.2 times greater with blood or fibrin in the anterior chamber on the first postoperative day. There was a linear relation between the frequency of being placed into the less-favorable-prognosis group and the occurrence of an immunoreaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663348

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  4 in total

Review 1.  [Tissue typing in perforating corneal transplantation].

Authors:  J Wachtlin; R Khaireddin; F Hoffmann
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

2.  Systemic ciclosporin A in high-risk keratoplasties.

Authors:  T Reinhard; R Sundmacher; P Heering
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

3.  In situ immunohistochemical analysis of cell adhesion molecules on human corneal endothelial cells.

Authors:  B J Foets; J J van den Oord; R Volpes; L Missotten
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

4.  Indications and outcomes of pediatric keratoplasty in a tertiary eye care center: A retrospective review.

Authors:  Rosario Gulias-Cañizo; Roberto Gonzalez-Salinas; Luis Fernando Hernandez-Zimbron; Everardo Hernandez-Quintela; Valeria Sanchez-Huerta
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.